Lomustine (Ceenu)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Nitrosourea, alkylates DNA and RNA and may inhibit certain key enzymatic reactions by carbamoylation of amino acids in proteins.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

Also known as

  • Generic names: CCNU, MeCCNU
  • Brand names: CeeNu, Gleostine
    • In 10/2013, Bristol-Myers Squibb discontinued production of their Lomustine brand name, CeeNu.[5] Lomustine is currently supplied as Gleostine by NextSource Biotechnology LLC.[6]

References

  1. 1.0 1.1 Lomustine (Ceenu) package insert
  2. Lomustine (Ceenu) package insert (locally hosted backup)
  3. Lomustine (Ceenu) patient drug information (Chemocare)
  4. Lomustine (Ceenu) patient drug information (UpToDate)
  5. Discontinued drug bulletin: Lomustine capsules (American Society of Health-System Pharmacists)
  6. NextSource Biotechnology Lomustine (CCNU) update